Tag results
Trials tagged with: "high risk mds"
The AML16 Trial will evaluate several relevant therapeutic questions in Acute Myeloid Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome. The trial is primarily designed for patients over 60 years, but younger patients who may not be considered suitable for the concurrent MRC AML Trial for
younger patients may also enter.
The AML 17 trial has two distinct parts:
i.For patients with acute myeloid leukaemia (AML), (other than acute promyelocytic leukaemia) and High Risk Myelodysplasia, as defined by the WHO Classification (2001) (Appendix A, protocol).
ii.For adults with acute promyelocytic leukaemia (APL).